Abstract
The record-breaking speed of vaccine development in response to the coronavirus outbreak relied in part on manufacturing infrastructure, technology development, and research tools previously built for oncologic products.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
